Novacyt S.A. Update on Notice of 2020 Full Year Results (3125C)
June 18 2021 - 2:00AM
UK Regulatory
TIDMNCYT
RNS Number : 3125C
Novacyt S.A.
18 June 2021
Novacyt S.A.
("Novacyt" or the "Company")
Update on Notice of 2020 Full Year Results
Paris, France and Camberley, UK - 18 June 2021 - Novacyt S.A.
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, announces that it will report its audited
financial results for the year ended 31 December 2020 on Tuesday 22
June 2021.
The Company has changed its reporting currency from Euro to
Great British Pounds (GBP) for these results, and will report in
GBP going forward, as the cost base of the business is now mainly
located in the UK and GBP is the largest invoicing currency for
sales. The results for the year ended 31 December 2019 will be
restated to GBP to provide the same currency comparison.
- End -
Novacyt SA
Graham Mullis, Chief Executive Officer
James McCarthy, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Numis Securities Limited (Joint Broker)
Freddie Barnfield / James Black
+44 (0)20 7260 1000
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com; y.petit@allegrafinance.com
FTI Consulting (International)
Victoria Foster Mitchell / Alex Shaw
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
alex.shaw@fticonsulting.com / Novacyt.group@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high-quality assays
and reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which
include major corporates.
For more information, please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORFLFEDREIDLIL
(END) Dow Jones Newswires
June 18, 2021 02:00 ET (06:00 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From Apr 2024 to May 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From May 2023 to May 2024